Nucletron Announces 2008 Results
VEENENDAAL, Apr. 24 /PRNewswire-AsiaNet/ --
- Strong Product Offerings and Leadership in Brachytherapy Contribute to
All-Time High
Nucletron, a global leader in radiation oncology, today announced strong
financial results in 2008 with net sales of EUR112.4 million (US $165
million). EBITDA in 2008 ended at an all time high (in constant currencies)
of EUR17 million with a strong fourth quarter contributing significantly to
the year-end success. Despite challenging global economic conditions,
Nucletron surpassed projections in 2008 due in large part to a renewed focus
on brachytherapy treatment and an expanding product offering in external beam
treatment planning software solutions.
Among the several advancements announced in 2008 was the introduction on
Oncentra(R) Brachy, a new comprehensive volume-based treatment planning
solution that optimizes cancer treatment planning with brachytherapy.
Additionally, Oncentra(R) RT Viewer received clearance in 2008. Oncentra RT
Viewer enables clinicians to review radiotherapy plans generated with a wide
variety of DICOM-compliant treatment planning systems in a Windows (PC)
environment.
"In the second half of 2008, we improved our focus on innovation and
marketing efforts, while strengthening our management team. Given our many
upcoming product releases in the months to come, we are on track to achieve
our 2009 goals as planned," said Jos Lamers, chief executive officer of
Nucletron.
About Nucletron
Nucletron is a global leader in Radiation Oncology, working with clinical
teams to realize innovative solutions that improve patient care. Nucletron
strives to offer the best possible choice of radiation modalities through
integrated products, software and services. Critical to the Nucletron
philosophy is the establishment of close working relationships with
individual clinical teams - reconfiguring traditional boundaries between
customer and solution provider. Many Nucletron employees have clinical
experience delivering oncology care, providing an in-depth understanding of
the complex needs of clinicians. For more information, visit
Source: Nucletron B V
NEWS 
